Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-28T11:23:39.276Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea in a Provincial Healthcare System

Published online by Cambridge University Press:  05 July 2016

Jenine R. Leal ,
Steven J. Heitman ,
John M. Conly ,
Elizabeth A. Henderson  and
Braden J. Manns
Jenine R. Leal*
Affiliation:
Infection Prevention and Control, Calgary and Area, Alberta Health Services (AHS), Calgary, Alberta, Canada Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
Steven J. Heitman
Affiliation:
Department of Medicine, University of Calgary and AHS, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary and AHS, Calgary, Alberta, Canada
John M. Conly
Affiliation:
Department of Medicine, University of Calgary and AHS, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary and AHS, Calgary, Alberta, Canada Department of Pathology and Laboratory Medicine, University of Calgary and AHS, Calgary, Alberta, Canada Snyder Institute for Chronic Diseases, University of Calgary and AHS, Calgary, Alberta, Canada Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
Elizabeth A. Henderson
Affiliation:
Infection Prevention and Control, Calgary and Area, Alberta Health Services (AHS), Calgary, Alberta, Canada Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary and AHS, Calgary, Alberta, Canada
Braden J. Manns
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Medicine, University of Calgary and AHS, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary and AHS, Calgary, Alberta, Canada
*
Address correspondence to Jenine R. Leal, MSc, Infection Prevention and Control, Alberta Health Services, Foothills Medical Centre, 801-South Tower, 1403-29th St NW, Calgary, Alberta T2N 2T9 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To conduct a full economic evaluation assessing the costs and consequences related to probiotic use for the primary prevention of Clostridium difficile–associated diarrhea (CDAD).

DESIGN

Cost-effectiveness analysis using decision analytic modeling.

METHODS

A cost-effectiveness analysis was used to evaluate the risk of CDAD and the costs of receiving oral probiotics versus not over a time horizon of 30 days. The target population modeled was all adult inpatients receiving any therapeutic course of antibiotics from a publicly funded healthcare system perspective. Effectiveness estimates were based on a recent systematic review of probiotics for the primary prevention of CDAD. Additional estimates came from local data and the literature. Sensitivity analyses were conducted to assess how plausible changes in variables impacted the results.

RESULTS

Treatment with oral probiotics led to direct costs of CDN $24 per course of treatment per patient. On average, patients treated with oral probiotics had a lower overall cost compared with usual care (CDN $327 vs $845). The risk of CDAD was reduced from 5.5% in those not receiving oral probiotics to 2% in those receiving oral probiotics. These results were robust to plausible variation in all estimates.

CONCLUSIONS

Oral probiotics as a preventive strategy for CDAD resulted in a lower risk of CDAD as well as cost-savings. The cost-savings may be greater in other healthcare systems that experience a higher incidence and cost associated with CDAD.

Infect Control Hosp Epidemiol 2016;37:1079–1086

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 37 , Issue 9 , September 2016 , pp. 1079 - 1086
Copyright
© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Honda, H, Dubberke, ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol 2014;30:54–62.CrossRefGoogle ScholarPubMed
2. Gase, KA, Haley, VB, Xiong, K, Van Antwerpen, C, Stricof, RL. Comparison of 2 Clostridium difficile surveillance methods: National Healthcare Safety Network’s laboratory-identified event reporting module versus clinical infection surveillance. Infect Control Hosp Epidemiol 2013;34:284–290.CrossRefGoogle ScholarPubMed
3. Bouza, E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012;18:5–12.CrossRefGoogle ScholarPubMed
4. Dubberke, ER, Carling, P, Carrico, R, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:628–645.CrossRefGoogle ScholarPubMed
5. Goldenberg, JZ, Ma, SS, Saxton, JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095.Google Scholar
6. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.Google Scholar
7. Gao, XW, Mubasher, M, Fang, CY, Reifer, C, Miller, LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636–1641.CrossRefGoogle ScholarPubMed
8. Maziade, PJ, Pereira, P, Goldstein, EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis 2015;60:S144–S147.CrossRefGoogle Scholar
9. Zimlichman, E, Henderson, D, Tamir, O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039–2046.CrossRefGoogle ScholarPubMed
10. Henrich, TJ, Krakower, D, Bitton, A, Yokoe, DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009;15:415–422.CrossRefGoogle ScholarPubMed
11. Drummond, M, Drummond, M. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.CrossRefGoogle Scholar
12. Pattani, R, Palda, VA, Hwang, SW, Shah, PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013;7:e56–e67.Google Scholar
13. Beausoleil, M, Fortier, N, Guenette, S, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007;21:732–736.CrossRefGoogle ScholarPubMed
14. Fansi, AAK, Guertin, JR, LeLorier, J. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ 2012;15:53–60.CrossRefGoogle Scholar
15. Szabo, S, Levy, A, Lozano-Ortega, G, et al. Incremental length of stay and costs associated with hospitalization for Clostridium difficile infection. In: Program and abstracts of the annual scientific meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society; October 2-6, 2013; San Francisco, CA. Abstract 1385.Google Scholar
16. Nanwa, N, Kendzerska, T, Krahn, M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 2015;110:511–519.CrossRefGoogle ScholarPubMed
17. Levy, AR, Szabo, SM, Lozano-Ortega, G, et al. Incidence and costs of Clostridium difficile infections in Canada. Open Forum . Infect Dis 2015;2:ofv076.Google Scholar
18. Lenoir-Wijnkoop, I, Nuijten, MJ, Craig, J, Butler, CC. Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. Front Pharmacol 2014;5:13.CrossRefGoogle ScholarPubMed
19. Campbell, R, Dean, B, Nathanson, B, Haidar, T, Strauss, M, Thomas, S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ 2013;16:440–448.Google Scholar
20. Maziade, PJ, Andriessen, JA, Pereira, P, Currie, B, Goldstein, EJ. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29:1341–1347.CrossRefGoogle Scholar